Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;9(3):77-87.
doi: 10.1177/2040622317743486. Epub 2017 Dec 14.

New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice

Sayam Dubash  1   2 , Dennis McGonagle  1   2 , Helena Marzo-Ortega  1   2
Affiliations
Review

New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice

Sayam Dubash et al. Ther Adv Chronic Dis. 2018 Mar.

Abstract

Axial spondyloarthritis (axSpA) is a chronic inflammatory condition that encompasses ankylosing spondylitis (AS) as well as non-radiographic axial disease (nr-axSpA) and can lead to chronic pain, structural damage and disability. The introduction of tumour necrosis factor inhibitor (TNFi) drugs for AS heralded a new era of drug therapeutics for what was previously a largely untreatable disease. This has now been expanded with the licensing of secukinumab, an interleukin 17A (IL-17A) inhibitor for the treatment of AS. Although biologic disease modifying antirheumatic drugs (bDMARDs) are not a first line treatment option in AS or axSpA, they are highly effective following incomplete or no response to physiotherapy and non-steroidal anti-inflammatory drugs (NSAIDs). Current research strategies aim to test whether the desired treatment goal of disease remission may now be achievable with early and stratified use of bDMARDs in both AS and nr-axSpA. This review summarizes the current literature on axSpA including pathophysiology, treatment indications, radiographic progression and the evidence for new developments in the treatment of both AS and nr-axSpA.

Keywords: IL-17A; JAK inhibitors; SpA; ankylosing spondylitis; anti-TNF; axSpA; axial psoriatic arthritis; biologic therapies; sacroiliitis; secukinumab.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The authors Professor Dennis McGonagle and Dr Helena Marzo-Ortega have received grants and/or honoraria from Abbvie, Celgene, Janssen, Elli-Lilly, MSD, Novartis, Pfizer and UCB.

Figures

Figure 1.
Figure 1.
ASAS classification criteria for axial SpA in patients with back pain for at least 3 months and under 45 years of age. *Sacroiliitis is defined by definite radiographic evidence by modified New York criteria or on MRI by ASAS consensus definition. Adapted from Rudwaleit and colleagues. ASAS, Assessment of Spondyloarthritis International Society; MRI, magnetic resonance imaging; SpA, spondyloarthritis.
Figure 2.
Figure 2.
ASAS40 and 20 responses to biologic DMARDs (bDMARDs) in ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpA) in phase III clinical trials. Direct comparison is limited given that there are no head-to-head studies comparing biologics. Partly adapted from Sieper et al. DMARD, disease modifying antirheumatic drug.
See this image and copyright information in PMC

References

    1. Lambert JR, Wright V. Psoriatic spondylitis: a clinical and radiological description of the spine in psoriatic arthritis. Q J Med 1977; 46: 411–425. - PubMed
    1. Linden S, Van Der Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum 1984; 27: 361–368. - PubMed
    1. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68(Suppl. 2): ii1–44. - PubMed
    1. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777–783. - PubMed
    1. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017; 42: 251–256. - PubMed